China Health Reform To Trim Hospital Involvement In Drug Sales
This article was originally published in PharmAsia News
Executive Summary
China's massive health care reform plan is set for release in March, according to Health Minister Chen Zhu. The country has faced soaring medical costs in recent years, leading to poverty in some areas. Reforms were made in four aspects of China's health system, including drug supplies. In that area, the plan is to reduce hospital involvement in drug sales to keep doctors from acting in the best interests of big pharmaceutical companies, Chen said. The other three reform areas are public health care, medical treatment and medical insurance. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.